{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:51:09Z","timestamp":1790211069293,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1440,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.bbmt.2010.08.005","type":"journal-article","created":{"date-parts":[[2010,8,15]],"date-time":"2010-08-15T04:42:44Z","timestamp":1281847364000},"page":"682-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T\u00a0Regulatory Cells"],"prefix":"10.1016","volume":"17","author":[{"given":"Jiehua","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Corringham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minya","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Chut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C.","family":"Mitrovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.08.005_bib1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","article-title":"Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Mielcarek","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.005_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1084\/jem.193.11.1285","article-title":"Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood","volume":"193","author":"Jonuleit","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.08.005_bib4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/jcp.21001","article-title":"The regulation of Foxp3 expression in regulatory CD4+CD25+ T cells: multiple pathways on the road","volume":"211","author":"Zhang","year":"2007","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A molecular perspective of CTLA-4 function","volume":"24","author":"Teft","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-3083.2009.02308.x","article-title":"How do regulatory T cells work?","volume":"70","author":"Corthay","year":"2009","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib7","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","article-title":"Foxp3-expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells","volume":"173","author":"Viguier","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib8","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2009-07-233676","article-title":"Granzyme B is not required for regulatory T cell\u2013mediated suppression of graft-versus-host disease","volume":"115","author":"Cai","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00005-008-0018-1","article-title":"The significance of Treg cells in defective tumor immunity","volume":"56","author":"Kosmaczewska","year":"2008","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.bbmt.2010.08.005_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcancer.2005.11.005","article-title":"Regulator T cells in immune surveillance and treatment of cancer","volume":"16","author":"Yamaguchi","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.immunol.25.022106.141527","article-title":"Improving T cell therapy for cancer","volume":"25","author":"Leen","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","article-title":"Regulatory T cells in cancer","volume":"108","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2009.06.053","article-title":"Intraepithelial effector (CD3+)\/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma","volume":"137","author":"Sinicrope","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbmt.2010.08.005_bib14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Anti\u2013CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Review","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2010.08.005_bib15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/CJI.0b013e318174a4fe","article-title":"CTLA-4: negative regulator of the immune response and a target for cancer therapy","volume":"31","author":"Keilholz","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2010.08.005_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14712590802643347","article-title":"The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MXD-010): a novel treatment strategy in cancer management","volume":"9","author":"Movva","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bbmt.2010.08.005_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CMR.0b013e328333bbc8","article-title":"Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen 4 blockade in advanced melonoma","volume":"20","author":"Agarwala","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.bbmt.2010.08.005_bib18","first-page":"9","article-title":"Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti\u2013CTLA-4 therapy","volume":"8","author":"Sun","year":"2008","journal-title":"Cancer Immun"},{"key":"10.1016\/j.bbmt.2010.08.005_bib19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2007-11-125435","article-title":"CTLA-4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion","volume":"112","author":"Kavanagh","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib20","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","article-title":"Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade","volume":"175","author":"Maker","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/0008-5472.CAN-08-3529","article-title":"Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF","volume":"69","author":"Fong","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.08.005_bib22","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.leu.2404720","article-title":"CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease","volume":"21","author":"Fevery","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.005_bib23","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2004-07-2561","article-title":"Anti-human CTLA-4 monoclonal antibody promotes expansion and immunity in\u00a0a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies","volume":"105","author":"May","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib24","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.4049\/jimmunol.177.7.4376","article-title":"Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo","volume":"177","author":"Read","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib25","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2006-02-003996","article-title":"High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT","volume":"108","author":"Rezvani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.semcancer.2005.11.008","article-title":"CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation","volume":"16","author":"Zorn","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib27","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2003-06-2073","article-title":"Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells","volume":"103","author":"Clark","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib28","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood-2004-03-1040","article-title":"Association of Foxp3 regulatory gene expression with graft-versus-host disease","volume":"104","author":"Miura","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaut.2007.12.002","article-title":"Separation of graft-vs-tumor effects from graft-vs-host disease in allogeneic hematopoietic cell transplantation","volume":"30","author":"Rezvani","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bbmt.2010.08.005_bib30","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib31","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.167.3.1245","article-title":"CD4+CD25high regulatory cells in human peripheral blood","volume":"167","author":"Baecher-Allan","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib32","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.08.005_bib33","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib34","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.11897","article-title":"CD4+CD25+FOXP3+ T regulatory cells reconstitution and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation","volume":"93","author":"Atanackovic","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.08.005_bib36","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2007-03-079160","article-title":"Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease","volume":"110","author":"Mielke","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.005_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melonoma: a randomized, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/intimm\/dxm014","article-title":"Activation-induced FOXP3 in human T effector cells dose not suppress proliferation or cytokine production","volume":"19","author":"Allen","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib39","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen 4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib40","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","author":"Hersh","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bbmt.2010.08.005_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-3083.2001.00985.x","article-title":"Regulation of surface and intracellular CTLA-4 on human peripheral T cells","volume":"54","author":"Wang","year":"2001","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.bbmt.2010.08.005_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14712590802643347","article-title":"The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer treatment","volume":"9","author":"Movva","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bbmt.2010.08.005_bib43","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:39:20Z","timestamp":1761057560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110003447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1083879110003447"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.08.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T\u00a0Regulatory Cells","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}